openPR Logo
Press release

Porphyria Targeting Therapies Market, 2021-2030

11-30-2021 06:23 AM CET | Health & Medicine

Press release from: Roots Analysis

Roots Analysis has announced the addition of “Porphyria Targeting Therapies Market, 2021-2030” report to its list of offerings.

Porphyria is a rare disorder that is characterized by excessive accumulation of porphyrin, a compound that aids in the formation of heme (an essential part of hemoglobin that helps carry oxygen in blood). Any anomaly caused by genetic or acquired abnormalities in heme biosynthesis (produced majorly in bone marrow and liver) can result in toxicity. It is worth highlighting that, till date, more than 1,000 mutations that can cause porphyria have been identified. However, prevalence of porphyria still remains unknown. Several treatment options such as gene therapy, proteasome inhibition and pharmacologic chaperones are currently being investigated among various other targeted treatment options.

To order this 130+ slides report, which features 90+ figures, please visit https://www.rootsanalysis.com/reports/porphyria-pipline-review.html.

Key Market Insights

15+ therapies have been / are being developed for the treatment of different types of porphyria
More than 70% of the aforementioned candidates are currently under clinical evaluation. Further, three therapies, namely Panhematin™, GIVLAARI® and SCENESSE®, have already been approved for the treatment of different types of porphyria.

Around 50% of the therapeutics are being developed as biologics
Majority (over 65%) of the abovementioned biologic drugs have been / are being designed for administration via the intravenous route. Furthermore, majority of the drugs (37%) have been / are being targeting acute intermittent porphyria.

Over 30% of the therapies have been / are being developed for erythropoietic protoporphyria
More than 65% the abovementioned therapies are currently being evaluated in clinical phases. Further, around 60% of the aforementioned therapy candidates are being developed as small molecules.

More than 45% of the players evaluating therapies for porphyria are small companies
North America has emerged as a key hub for the development of porphyria therapies, featuring the presence of 65% developers. The developer landscape is further dominated by players that have been established between 2001-2010, representing around 45% of the total number of stakeholders.

A number of clinical trials evaluating therapies for porphyria, have been registered
Majority of the clinical studies have been completed. More than 30% of the overall trials are phase I studies. Further, it is worth noting that, most of the trials (~ 60%) focused on porphyria therapies were registered post-2010.

To order this 130+ slides report, which features 90+ figures, please visit https://www.rootsanalysis.com/reports/porphyria-pipline-review.html.

Partnership activity in this field has increased at a CAGR of 9.6%, between 2018 and 2020
More than 70% of the reported deals were established post-2018, with the maximum activity being reported in 2019 and 2020. Majority of the instances captured in the report were product distribution / commercialization agreements (~45%).

380+ articles have been published related to porphyria, since January 2018
Close to 20% publications mentioned in the report were focused on the assessment of therapeutics that have been / are being developed for the treatment of erythropoietic protoporphyria. Example of prominent journals include (in decreasing order of number of publications) Molecular Genetics, Orphanet Journal of Rare Diseases, British Journal of Dermatology and Molecular Genetics, and Metabolism Reports.

Around 15 eminent individuals were identified as key opinion leaders (KOLs) in this domain
More than 65% of these KOLs were observed to be associated with organizations based in US, followed by those affiliated to institutes in Spain (20%) and South Africa (7%). Further, over 65% of the KOLs are currently affiliated to academic institutes, such as schools and universities.

North America is anticipated to capture over 60% of the global market share in 2030
In 2030, more than 50% of the market revenues are expected to be generated from sales of therapeutics intended for the treatment of erythropoietic protoporphyria and porphyria cutanea tarda. Further, therapies designed for oral route of administration are expected to occupy a larger share (51%) of the overall market, in the foreseen future.

To request a sample copy / brochure of this report, please visit this link.

Key Questions Answered
 What are the prevalent R&D trends related to Porphyria?
 What are the key challenges faced by stakeholders engaged in this domain?
 What are the principal therapies developed by the companies in this domain?
 Who are the leading industry and non-industry players in this market?
 What are the key geographies where research on porphyria is actively being conducted?
 Who are the key investors in this domain?
 Who are the key opinion leaders / experts in this field?
 What kind of partnership models are commonly adopted by industry stakeholders?
 What are the factors that are likely to influence the evolution of this upcoming market?
 How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the porphyria therapies market has been analyzed across the following segments:

 Drug
 GIVLAARI®
 Panhematin®
 SCENESSE®
 MT-7117
 Colestid
 HARVONI®

 Type of Porphyria
 Acute Hepatic Porphyria
 Acute Intermittent Porphyria
 Erythropoietic Protoporphyria
 Hereditary Coproporphyria
 Porphyria Cutanea Tarda
 Variegate Porphyria
 X-Linked Porphyria

 Route of Administration
 Oral
 Intravenous
 Subcutaneous

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific

The research includes profiles of key players (listed below); each profile features a brief overview of company, pipeline details, recent developments (including collaborations and expansions) and an informed future outlook.
 Agios Pharmaceutical
 Alnylam Pharmaceuticals
 Clinuvel Pharmaceuticals
 Disc Medicine
 Mitsubishi Tanabe Pharma
 Moderna Therapeutics
 Palatin Technologies
 Recordati Rare Diseases

For additional details, please visit https://www.rootsanalysis.com/reports/porphyria-pipline-review.html or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
2. Soft Tissue Sarcoma: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
3. Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnson@rootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnson@rootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/

We specialise in analysing areas which have lacked quality research so far or require more focussed understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Porphyria Targeting Therapies Market, 2021-2030 here

News-ID: 2478736 • Views:

More Releases from Roots Analysis

Antibody Discovery Market Set to Soar to $6.6 Billion by 2035
Antibody Discovery Market Set to Soar to $6.6 Billion by 2035
Antibodies, also known as immunoglobulins, are Y-shaped glycoproteins that are produced by the immune system in response to foreign molecules (antigens) that enter the body. The term antigen refers to any substance that is capable of inducing an immune response, encompassing a diverse range of entities, including viruses, fungi, bacteria, proteins on the surface of cells, and non-living substances, such as toxins, chemicals and foreign particles. The global antibody discovery
Biopsy is defined as a procedure of removing or extracting tissue from the body through various methods, such as surgical, needle, laparoscopic techniques.
Biopsy is defined as a procedure of removing or extracting tissue from the body …
The global virtual biopsy market, valued at USD 0.73 billion in 2024, is projected to reach USD 0.78 billion in 2025 and USD 3.02 billion by 2035, representing a CAGR of 14.47% during the forecast period. This procedure plays a crucial role in the diagnosis or monitoring of certain medical conditions such as inflammatory disorders, immune disorders, oncological conditions, and several infections. By analyzing the cellular composition of the extracted tissue,
Big data in healthcare: transforms patient care, enhances efficiency, and unlocks new possibilities for personalized medicine
Big data in healthcare: transforms patient care, enhances efficiency, and unlock …
The global big data in healthcare market size is estimated to grow from USD 78 billion in 2024 to USD 540 billion by 2035, representing a CAGR of 19.20% during the forecast period till 2035. Big data in healthcare is the collection of large amounts of unstructured data from various sources, such as medical research, biometric data, electronic medical records, Internet of Medical Things (IoMT), social media, payer records, omics
AI In Oncology Market CAGR to Exceed 14%, Due to The Growing Demand for Diagnosis of Cancer Indications | Roots Analysis
AI In Oncology Market CAGR to Exceed 14%, Due to The Growing Demand for Diagnosi …
With an aim to counter the rising number of cancer cases across the globe, artificial intelligence has emerged as the key enabler in cancer treatment to generate better clinical outcomes. According to the World Health Organization (WHO), in the healthcare sector, oncology is one of the important sections primarily because cancer is the second leading causes of mortality worldwide. It is estimated that in 2022, about 1.9 million new cancer cases

All 5 Releases


More Releases for Porphyria

What's Driving the Acute Intermittent Porphyria Market 2025-2034: Impact Of Risi …
What Are the Projections for the Size and Growth Rate of the Acute Intermittent Porphyria Market? There has been a robust growth in the market size of acute intermittent porphyria in the past few years. The market that was valued at $4.37 billion in 2024, is projected to increase to $4.66 billion in 2025, marking a compound annual growth rate (CAGR) of 6.7%. Factors such as increasing healthcare spending, a surge
Acute Intermittent Porphyria Market Acute Intermittent Porphyria Treatments, Siz …
According to a new report published by CoherentMI The acute intermittent porphyria market is estimated to be valued at USD 1.43 Billion in 2024 and is expected to reach USD 2.17 Billion by 2031, growing at a compound annual growth rate (CAGR) of 6.1% from 2024 to 2031. The Global Acute Intermittent Porphyria Market has recently been analyzed and explored by CoherentMI in their latest market research report. The
Enhance Genetic Testing Module for Acute Intermittent Porphyria
The "Acute Intermittent Porphyria Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats,
Swedish Porphyria Therapeutics Market to Signify Strong Growth by 2023-2029
The Swedish Porphyria Therapeutics Market size is expected to grow at an annual average of CAGR 73% during the forecast period (2023-2029). Swedish porphyria is a rare, inherited disorder that mainly affects the skin and nervous system. The signs and symptoms of this disorder can vary from person to person. Some people with Swedish porphyria may have mild symptoms, while others may have more serious problems. And Swedish porphyria is
Porphyria Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results | Alny …
Porphyria is a group of disorders including cutaneous porphyria and acute porphyria. Cutaneous porphyria affects the skin while acute porphyria affects the nervous system. Porphyria cutanea tarda is the most common type of porphyria prevalent in the U.S. Download the sample report at: https://www.pharmaproff.com/request-sample/1043 The common symptoms of porphyria are abdominal pain, chest pain, increased blood pressure, increased heart rate, muscle weakness, cramping, blisters, itching, swelling, constipation, vomiting, mental disorders,
Global Swedish Porphyria Industry Assesment report 2018-2025
Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias. In 2018, the global Swedish Porphyria market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. In this study, 2017 has been considered as the base year